AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

REVB · NASDAQ · Biotechnology

Revelation Biosciences (REVB)

Develops Gemini immunomodulators for acute kidney injury and chronic kidney disease.

$0.9403

Pre-market−0.08 (−7.81%)

At close$1.02(+3.39%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Insiders7 holders · as of Aug 18, 2026	21.51%	856.8K shares
Strategic holders1 holder · as of May 15, 2026	8.11%	323.2K shares
Otherremainder	70.38%	2.80M shares

3.98M company shares as of Sep 3, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
James RolkeInsiderdirector, officer: Chief Executive Officer	10.61%	422,814	Form 4filed Aug 18, 2026 ↗
Armistice Capital, LLCStrategic	8.11%	323,241	13Gfiled May 15, 2026 ↗
Chester Stanley III ZygmontInsiderofficer: Chief Financial Officer	7.53%	300,136	Form 4filed Aug 18, 2026 ↗
Jess RoperInsiderdirector	1.13%	44,839	Form 4filed Aug 18, 2026 ↗
Jennifer CarverInsiderdirector	1.12%	44,769	Form 4filed Aug 18, 2026 ↗
Lakhmir S. ChawlaInsiderdirector	1.11%	44,169	Form 4filed Aug 18, 2026 ↗
Mitchell P. KopinInsider	0.00%	32	13Gfiled Feb 21, 2023 ↗
George F. TidmarshInsiderdirector	0.00%	24	Form 4filed Feb 13, 2025 ↗
Andrew M. Weiss, Ph.d.Insider	—5.37% of class, as filed	—	13Gfiled Feb 9, 2022 ↗
Axa S.a.Insider	—8.32% of class, as filed	—	13Gfiled Feb 14, 2023 ↗
GlassInsider	—8.00% of class, as filed	—	13Gfiled Oct 16, 2020 ↗
Investment ManagementInstitution	—11.03% of class, as filed	—	13Gfiled Aug 10, 2021 ↗
Lind Global Fund II LPInstitution	—5.20% of class, as filed	—	13Gfiled Feb 21, 2023 ↗
Sabby Management, LLCStrategic	—9.60% of class, as filed	—	13Gfiled Jan 20, 2026 ↗
WongInsider	—5.80% of class, as filed	—	13Gfiled Jan 20, 2022 ↗
Andreas Typaldos¹Insiderdirector, 10 percent owner, officer: Chief Executive Officer	0.00%	9	Form 4filed Dec 31, 2020 ↗
Kimon Angelides²Insiderdirector	0.00%	0	Form 4filed Oct 9, 2020 ↗
William Howard Carson³Insiderdirector	0.00%	0	Form 4filed Mar 11, 2021 ↗
Barry Dennis²Insiderdirector	0.00%	0	Form 4filed Oct 9, 2020 ↗
David Dobkin²Insiderdirector	0.00%	0	Form 4filed Oct 9, 2020 ↗
Anthony Hayes²Insiderdirector	0.00%	0	Form 4filed Oct 9, 2020 ↗
Robert D. Nicholson²Insiderdirector	0.00%	0	Form 4filed Oct 9, 2020 ↗
Lawrence Feis⁴Insider10 percent owner	0.00%	0	Form 4filed Jan 11, 2022 ↗
Sean H. Fitzpatrick^1,5Insiderdirector, 10 percent owner, officer: Chief Executive Officer	0.00%	0	Form 4filed Dec 31, 2020 ↗

Last filed Dec 31, 2020; leaving the company requires no filing. Not in the bar.
Last filed Oct 9, 2020; leaving the company requires no filing. Not in the bar.
Last filed Mar 11, 2021; leaving the company requires no filing. Not in the bar.
Last filed Jan 11, 2022; leaving the company requires no filing. Not in the bar.
Sean H. Fitzpatrick reports a block also reported by Andreas Typaldos; it is counted once, under Andreas Typaldos.

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Sabby Management, LLC	9.60%		13G	Jan 20, 2026 ↗
Armistice Capital, LLC	7.80%	323.2K	13G	May 15, 2026 ↗

Revelation Biosciences (REVB)

Breakdown13F · 13D/G · Form 4

Top shareholders13F · 13D/G · Form 4

Institutions13F

Ownership statements13D/G · 5% or more, as filed

Insider tradesForm 4

Latest trades

CongressHouse and Senate disclosures